MCID: AMP013
MIFTS: 50

Ampulla of Vater Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Ampulla of Vater Cancer

MalaCards integrated aliases for Ampulla of Vater Cancer:

Name: Ampulla of Vater Cancer 12 12 15
Ampulla of Vater Carcinoma 12 15 17
Ampullary Carcinoma 12 60
Malignant Tumour of Ampulla of Vater 12
Carcinoma of the Ampulla of Vater 60
Carcinoma of Ampulla of Vater 12
Ampulloma 60

Characteristics:

Orphanet epidemiological data:

60
carcinoma of the ampulla of vater
Inheritance: Not applicable; Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:10020 DOID:4932
ICD9CM 36 156.2
NCIt 51 C3536 C3908
SNOMED-CT 69 93668007
ICD10 34 C24.1
ICD10 via Orphanet 35 C24.1
UMLS via Orphanet 75 C0262401
Orphanet 60 ORPHA300557

Summaries for Ampulla of Vater Cancer

Disease Ontology : 12 An ampulla of Vater cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

MalaCards based summary : Ampulla of Vater Cancer, also known as ampulla of vater carcinoma, is related to ampulla of vater adenocarcinoma and adenoma. An important gene associated with Ampulla of Vater Cancer is KRT7 (Keratin 7), and among its related pathways/superpathways are Developmental Biology and Cytokine Signaling in Immune system. The drugs Oxaliplatin and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include lung, pancreas and liver, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Ampulla of Vater Cancer

Diseases related to Ampulla of Vater Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 273)
# Related Disease Score Top Affiliating Genes
1 ampulla of vater adenocarcinoma 31.6 CDX2 KRT17 KRT20 KRT7 MUC1
2 adenoma 30.2 KRAS PTGS2 TP53
3 small cell carcinoma 30.2 KRT20 KRT7 TP53
4 adenosquamous carcinoma 30.1 KRAS KRT7 MUC1 TP53
5 squamous cell carcinoma 30.0 HRAS MUC1 PTGS2 TP53
6 gastritis 29.9 CDX2 MUC6 PTGS2
7 familial adenomatous polyposis 29.8 KRAS PTGS2 TP53
8 papilloma 29.7 KRT20 KRT7 TP53
9 gallbladder cancer 29.5 KRAS MUC1 PTGS2 TP53
10 adenocarcinoma 29.4 HRAS KRAS MUC1 PTGS2 TP53
11 bladder cancer 29.3 HRAS KRAS KRT20 TP53
12 intrahepatic cholangiocarcinoma 28.8 CDX2 KRAS KRT20 KRT7 MUC1 TP53
13 cholangiocarcinoma 28.8 CDX2 KRAS KRT20 KRT7 MUC1 PTGS2
14 gastric cancer 28.6 CDX2 KRAS KRT20 MUC6 PTGS2 TP53
15 ampulla of vater neoplasm 11.4
16 ampulla of vater squamous cell carcinoma 11.4
17 ampulla of vater adenosquamous carcinoma 11.4
18 large cell neuroendocrine carcinoma 10.5
19 bile reflux 10.4 CDX2 PTGS2
20 nasal cavity cancer 10.4 CDX2 KRT7
21 epithelial predominant wilms' tumor 10.4 CDX2 KRT7
22 endosalpingiosis 10.4 KRT7 MUC1
23 nodular hidradenoma 10.4 KRT7 MUC1
24 parachordoma 10.4 KRT7 MUC1
25 sertoli-leydig cell tumor 10.4 KRT7 MUC1
26 hidradenoma 10.4 KRT7 MUC1
27 spindle cell sarcoma 10.4 KRT7 MUC1
28 secretory meningioma 10.4 KRT7 MUC1
29 bile duct mucoepidermoid carcinoma 10.4 KRT7 MUC1
30 sclerosing hemangioma 10.4 KRT7 MUC1
31 middle ear adenoma 10.4 KRT7 MUC1
32 lipoadenoma 10.4 KRT7 MUC1
33 monophasic synovial sarcoma 10.4 KRT7 MUC1
34 hepatoid adenocarcinoma 10.4 CDX2 MUC1
35 well-differentiated liposarcoma 10.4 KRT7 MUC1
36 large cell acanthoma 10.4 KRT17 KRT7
37 pregnancy adenoma 10.4 KRT17 KRT7
38 colonic benign neoplasm 10.4 KRAS PTGS2
39 bowen's disease 10.4 KRT17 KRT7
40 alveoli adenoma 10.4 KRAS KRT7
41 polyposis syndrome, hereditary mixed, 1 10.4 MUC6 PTGS2
42 syringocystadenoma papilliferum 10.3 KRAS MUC1
43 endocervical carcinoma 10.3 KRT7 MUC6
44 microcystic adenoma 10.3 MUC1 MUC6
45 ovary neuroendocrine neoplasm 10.3 CDX2 KRT7
46 chronic ethmoiditis 10.3 MUC1 MUC6
47 ethmoid sinusitis 10.3 MUC1 MUC6
48 vulvar disease 10.3 KRT7 TP53
49 female reproductive endometrioid cancer 10.3 KRT7 TP53
50 recurrent respiratory papillomatosis 10.3 PTGS2 TP53

Graphical network of the top 20 diseases related to Ampulla of Vater Cancer:



Diseases related to Ampulla of Vater Cancer

Symptoms & Phenotypes for Ampulla of Vater Cancer

GenomeRNAi Phenotypes related to Ampulla of Vater Cancer according to GeneCards Suite gene sharing:

27 (show all 31)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.8 HRAS KRAS MUC1
2 Decreased viability GR00106-A-0 9.8 KRAS
3 Decreased viability GR00221-A-1 9.8 HRAS KRAS
4 Decreased viability GR00221-A-2 9.8 HRAS KRAS
5 Decreased viability GR00221-A-3 9.8 HRAS
6 Decreased viability GR00301-A 9.8 KRAS
7 Decreased viability GR00381-A-1 9.8 KRAS
8 Decreased viability GR00402-S-2 9.8 HRAS KRAS MUC1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.72 KRT17
10 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.72 KRAS
11 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.72 KRAS
12 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.72 KRT17
13 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.72 KRAS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.72 KRT17
15 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.72 KRAS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.72 HRAS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.72 KRT17
18 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.72 HRAS KRAS KRT17
19 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.72 KRT17
20 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.72 KRT17
21 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.72 KRAS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.72 KRT17
23 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.72 HRAS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.72 KRT17
25 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.72 KRT17
26 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.72 KRAS KRT17
27 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.72 KRAS
28 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.72 KRAS
29 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.72 HRAS
30 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.72 KRAS
31 Decreased cell migration GR00055-A-1 9.46 HRAS KRAS MUC1 PRKACA

MGI Mouse Phenotypes related to Ampulla of Vater Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.63 CDX2 HRAS KRAS KRT17 PTGS2 TP53
2 neoplasm MP:0002006 9.43 CDX2 HRAS KRAS PRKACA PTGS2 TP53
3 renal/urinary system MP:0005367 9.1 HRAS KRAS KRT7 PRKACA PTGS2 TP53

Drugs & Therapeutics for Ampulla of Vater Cancer

Drugs for Ampulla of Vater Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2
leucovorin Approved Phase 3,Phase 1,Phase 2 58-05-9 143 6006
3
Levoleucovorin Approved, Investigational Phase 3,Phase 1,Phase 2 68538-85-2
4
Cisplatin Approved Phase 3,Phase 1 15663-27-1 2767 441203 84093
5
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
6
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
8 Vitamin B Complex Phase 3,Phase 1,Phase 2
9 Vitamin B9 Phase 3,Phase 1,Phase 2
10 Antidotes Phase 3,Phase 1,Phase 2
11 Trace Elements Phase 3,Phase 1,Phase 2
12 Folate Phase 3,Phase 1,Phase 2
13 Protective Agents Phase 3,Phase 1,Phase 2
14 Vitamins Phase 3,Phase 1,Phase 2
15 Nutrients Phase 3,Phase 1,Phase 2
16 Micronutrients Phase 3,Phase 1,Phase 2
17 Antibiotics, Antitubercular Phase 3,Not Applicable
18 Anti-Bacterial Agents Phase 3,Not Applicable
19 Antiemetics Phase 3
20 Hematinics Phase 3
21 Emetics Phase 3
22
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
23
Bevacizumab Approved, Investigational Phase 2 216974-75-3
24
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
25
Irinotecan Approved, Investigational Phase 1, Phase 2 100286-90-6, 97682-44-5 60838
26
Paclitaxel Approved, Vet_approved Phase 1, Phase 2,Phase 2 33069-62-4 36314
27
Coal tar Approved Phase 1, Phase 2 8007-45-2
28
Calcium Approved, Nutraceutical Phase 1, Phase 2 7440-70-2 271
29
s 1 (combination) Phase 2
30 Immunosuppressive Agents Phase 2,Phase 1
31 Antimetabolites, Antineoplastic Phase 2,Phase 1
32 Antimetabolites Phase 2,Phase 1
33 Antimitotic Agents Phase 2,Phase 1
34 Immunologic Factors Phase 2,Phase 1
35 Antiviral Agents Phase 2,Phase 1
36 Anti-Infective Agents Phase 2,Phase 1,Not Applicable
37 Immunoglobulin G Phase 2
38 Endothelial Growth Factors Phase 2
39 Angiogenesis Inhibitors Phase 2
40 Immunoglobulins Phase 2,Phase 1
41 Mitogens Phase 2
42 Antibodies Phase 2,Phase 1
43 Angiogenesis Modulating Agents Phase 2
44 Antibodies, Monoclonal Phase 2
45 Antineoplastic Agents, Immunological Phase 2
46 topoisomerase I inhibitors Phase 1, Phase 2
47 Topoisomerase Inhibitors Phase 1, Phase 2
48 Albumin-Bound Paclitaxel Phase 1, Phase 2,Phase 2
49 Hormones Phase 1, Phase 2
50 Calcium, Dietary Phase 1, Phase 2

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
2 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
3 Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma) Unknown status NCT01180153 Phase 2 S-1 oxaliplatin
4 A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers Completed NCT00660699 Phase 2 Gemcitabine;Docetaxel
5 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
6 Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma Completed NCT01208103 Phase 2 Capecitabine;Oxaliplatin
7 Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer Completed NCT02333188 Phase 1, Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
8 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Active, not recruiting NCT02810418 Phase 1, Phase 2 LMB-100;Nab-Paclitaxel
9 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
10 Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers Completed NCT00183846 Phase 1 irinotecan
11 ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery Completed NCT01825603 Phase 1 ADH-1;Cisplatin;Gemcitabine Hydrochloride
12 A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer Recruiting NCT02908451 Phase 1
13 Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Active, not recruiting NCT01643499 Phase 1 oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
14 ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT02351765 Phase 1 Acelarin;Cisplatin
15 Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer Unknown status NCT02238613 Not Applicable
16 Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP) Unknown status NCT02656134
17 T-EUS for Gastrointestinal Disorders: A Multicenter Registry Unknown status NCT01522573
18 Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders Unknown status NCT01438385
19 Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT) Completed NCT02081131 Not Applicable
20 Comparison Between Fully Covered Metal Stents and Plastic Stents in Preoperative Biliary Drainage Completed NCT01789502 Not Applicable
21 Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers Completed NCT01134276 Not Applicable
22 Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography: Precut Versus Conventional Cannulation Completed NCT02477228 Not Applicable
23 Fatigue and Pancreas and Bile Duct Cancer Study Completed NCT00902759 Early Phase 1
24 Reconstruction Following Pancreaticoduodenectomy: A Randomized Clinical Trial of Pancreaticojejunostomy vs Pancreaticogastomy Completed NCT00841607 Not Applicable
25 Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer Completed NCT00409864 Not Applicable
26 Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy Completed NCT00639314 Not Applicable
27 Randomized Controlled Trial on Pancreatic Stent Tube in Pancreaticoduodenectomy Completed NCT00628186 Not Applicable
28 Endobiliary RFA for Unresectable Malignant Biliary Strictures Recruiting NCT01844245 Not Applicable
29 Biliary Cancer in Italy: a Study on Cholangiocarcinoma cAUSEs and Risk Factors Recruiting NCT02665494
30 EUS Evaluation of CBD Diameter in Malignant Obstructive Jaundice Recruiting NCT03494023
31 Enteral Nutrition After Pancreaticoduodenectomy Recruiting NCT03150615 Not Applicable
32 Periampullary Lesions Via ERCP in Assuit University Hospital Recruiting NCT03185390 Not Applicable
33 Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction Patient Recruiting NCT02958059 Not Applicable
34 Effect of Cap-assisted Esophagogastroduodenoscopy on Observation of Major Duodenal Papilla Recruiting NCT03219619 Not Applicable
35 Margin Status After Pancreaticoduodenectomy for Cancer Active, not recruiting NCT03267966 Not Applicable

Search NIH Clinical Center for Ampulla of Vater Cancer

Genetic Tests for Ampulla of Vater Cancer

Anatomical Context for Ampulla of Vater Cancer

MalaCards organs/tissues related to Ampulla of Vater Cancer:

42
Lung, Pancreas, Liver, Colon, Ovary, Small Intestine, Appendix

Publications for Ampulla of Vater Cancer

Articles related to Ampulla of Vater Cancer:

(show all 35)
# Title Authors Year
1
The Prognostic Relevance of the New 8th Edition of the Union for International Cancer Control Classification of TNM Staging for Ampulla of Vater Carcinoma. ( 30790111 )
2019
2
Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis. ( 30451797 )
2019
3
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations. ( 27611608 )
2018
4
Ampulla of Vater carcinoma: Molecular landscape and clinical implications. ( 30487949 )
2018
5
Impact of preoperative endoscopic cholangiography and biliary drainage in Ampulla of Vater cancer. ( 29549909 )
2018
6
Validation of the eighth edition of the American Joint Committee on Cancer staging system for ampulla of Vater cancer. ( 29452703 )
2018
7
PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. ( 28502094 )
2017
8
Proposed new staging system for ampulla of Vater cancer with greater discriminatory ability: multinational study from eastern and western centers. ( 28660632 )
2017
9
Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. ( 26974670 )
2016
10
Transduodenal Ampullectomy for the Treatment of Early-Stage Ampulla of Vater Cancer. ( 26546182 )
2016
11
Ampulla of Vater carcinoma in real-world clinical practice: a case series. ( 25908045 )
2015
12
Metachronous Ampulla of Vater Carcinoma after Curative-Intent Surgery for Klatskin Tumor. ( 26305204 )
2015
13
Prognostic impact of immunohistochemical expression of CK7 and CK20 in curatively resected ampulla of Vater cancer. ( 26603157 )
2015
14
Survival Benefit of Adjuvant Chemoradiotherapy in Patients With Ampulla of Vater Cancer: A Systematic Review and Meta-analysis. ( 25775067 )
2015
15
Knockdown of anterior gradient 2 expression extenuates tumor-associated phenotypes of SNU-478 ampulla of Vater cancer cells. ( 25367337 )
2014
16
Clinical value of serum CA19-9 as a prognostic factor for the ampulla of Vater carcinoma. ( 23933785 )
2013
17
Proposed indications for limited resection of early ampulla of Vater carcinoma: clinico-histopathological criteria to confirm cure. ( 22203456 )
2012
18
Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. ( 21882202 )
2012
19
Surgical outcomes and prognostic factors for ampulla of Vater cancer. ( 21737384 )
2011
20
Significance analysis of histologic type and perineural invasion as prognostic factors after curative resection of ampulla of Vater carcinoma. ( 20698243 )
2010
21
Spontaneous choledochoduodenal fistula after metallic biliary stent placement in a patient with ampulla of vater carcinoma. ( 20431778 )
2009
22
[Determinants of long-term survival after pancreaticoduodenectomy for ampulla of Vater carcinoma]. ( 20223115 )
2009
23
Role of adjuvant chemoradiotherapy for ampulla of Vater cancer. ( 19394162 )
2009
24
Feasibility of endoscopic papillectomy in early stage ampulla of Vater cancer. ( 19032444 )
2009
25
Prognostic relevance of lymph node ratio and number of resected nodes after curative resection of ampulla of Vater carcinoma. ( 18712568 )
2008
26
Factors influencing recurrence after curative resection for ampulla of Vater carcinoma. ( 17326125 )
2007
27
Periampullary choledochoduodenal fistula associated with ampulla of Vater carcinoma. ( 17404887 )
2007
28
The clinicopathologic and immunohistochemical characteristics of ampulla of Vater carcinoma: the intestinal type is associated with a better prognosis. ( 18019683 )
2007
29
Transduodenal local resection for low-risk group ampulla of vater carcinoma. ( 18158802 )
2007
30
Can endoscopic resection be applied for early stage ampulla of Vater cancer? ( 16650538 )
2006
31
Expression of E-cadherin and beta-catenin in the adenoma-carcinoma sequence of ampulla of Vater cancer. ( 16506371 )
2006
32
Allelotype of ampulla of Vater cancer: highly frequent involvement of chromosome 11. ( 15024645 )
2004
33
Expression of cyclooxygenase-2 and its correlation with clinicopathologic factors of ampulla of vater cancer. ( 12692419 )
2003
34
Clinics in diagnostic imaging (79). Ampulla of Vater carcinoma. ( 12680532 )
2002
35
Prognostic value of MIB-1 index and DNA ploidy in resectable ampulla of Vater carcinoma. ( 10203085 )
1999

Variations for Ampulla of Vater Cancer

Expression for Ampulla of Vater Cancer

Search GEO for disease gene expression data for Ampulla of Vater Cancer.

Pathways for Ampulla of Vater Cancer

Pathways related to Ampulla of Vater Cancer according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.34 HRAS KRAS KRT17 KRT20 KRT7 PRKACA
2
Show member pathways
13.16 HRAS KRAS MUC1 PRKACA PTGS2 TP53
3
Show member pathways
12.87 HRAS KRAS KRT17 KRT20 PRKACA
4
Show member pathways
12.81 HRAS KRAS PRKACA PTGS2 TP53
5
Show member pathways
12.8 HRAS KRAS PRKACA PTGS2 TP53
6 12.64 HRAS KRAS PRKACA TP53
7
Show member pathways
12.64 CDX2 HRAS KRAS TP53
8
Show member pathways
12.62 HRAS KRAS PRKACA PTGS2
9 12.6 HRAS KRAS PRKACA PTGS2 TP53
10
Show member pathways
12.59 HRAS KRAS PTGS2 TP53
11
Show member pathways
12.58 HRAS KRAS PRKACA TP53
12
Show member pathways
12.4 HRAS KRAS MUC1 TP53
13 12.37 KRT17 KRT20 KRT7 MUC1
14 12.33 HRAS KRAS PTGS2 TP53
15 12.17 HRAS KRAS PRKACA TP53
16
Show member pathways
12.11 HRAS KRAS PTGS2
17
Show member pathways
12.09 HRAS KRAS PRKACA
18 12.07 HRAS KRAS TP53
19
Show member pathways
12.07 HRAS KRAS TP53
20 12.06 HRAS KRAS PRKACA TP53
21
Show member pathways
12.04 HRAS KRAS TP53
22 12.04 HRAS KRAS PRKACA TP53
23 12.03 HRAS KRAS TP53
24
Show member pathways
12.03 HRAS KRAS PRKACA
25 11.97 HRAS KRAS PRKACA
26
Show member pathways
11.94 HRAS KRAS TP53
27 11.93 HRAS KRAS PRKACA
28 11.89 HRAS KRAS TP53
29 11.89 KRAS PRKACA PTGS2 TP53
30 11.87 HRAS KRAS TP53
31 11.86 MUC1 PTGS2 TP53
32 11.84 HRAS KRAS TP53
33
Show member pathways
11.8 HRAS KRAS PRKACA TP53
34 11.71 HRAS KRAS PRKACA
35 11.64 KRT17 PRKACA TP53
36 11.62 HRAS KRAS PRKACA TP53
37 11.58 HRAS KRAS TP53
38 11.52 HRAS KRAS PRKACA PTGS2
39 11.5 HRAS KRAS TP53
40 11.48 HRAS KRAS TP53
41 11.48 HRAS KRAS TP53
42
Show member pathways
11.43 HRAS KRAS MUC1 MUC6 PRKACA
43 11.26 HRAS KRAS PTGS2
44 11.19 HRAS KRAS TP53
45
Show member pathways
11.17 HRAS KRAS
46
Show member pathways
11.12 HRAS KRAS
47 11.06 HRAS KRAS
48 10.99 HRAS KRAS
49 10.75 HRAS KRAS
50 10.47 HRAS KRAS PRKACA

GO Terms for Ampulla of Vater Cancer

Cellular components related to Ampulla of Vater Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 8.8 KRT17 KRT20 KRT7

Biological processes related to Ampulla of Vater Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.8 CDX2 HRAS KRAS PTGS2
2 keratinization GO:0031424 9.71 KRT17 KRT20 KRT7
3 cell aging GO:0007569 9.52 HRAS TP53
4 cellular response to gamma radiation GO:0071480 9.51 HRAS TP53
5 cornification GO:0070268 9.5 KRT17 KRT20 KRT7
6 positive regulation of cell cycle arrest GO:0071158 9.48 PRKACA TP53
7 regulation of long-term neuronal synaptic plasticity GO:0048169 9.46 HRAS KRAS
8 positive regulation of protein export from nucleus GO:0046827 9.43 PRKACA TP53
9 intermediate filament organization GO:0045109 9.4 KRT17 KRT20
10 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.37 MUC1 TP53
11 cytokine-mediated signaling pathway GO:0019221 9.35 KRAS MUC1 PRKACA PTGS2 TP53
12 Ras protein signal transduction GO:0007265 9.33 HRAS KRAS TP53
13 response to isolation stress GO:0035900 9.26 HRAS KRAS
14 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.02 HRAS KRAS MUC1 MUC6 PRKACA

Sources for Ampulla of Vater Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....